Association of Body Mass Index and Age with Positive Receptors Expression and Metastasis Status Subtypes in Iraqi Women with Breast Cancer
DOI:
https://doi.org/10.61841/0a8t2214Keywords:
Breast cancer, Estrogen receptors alpha and beta (ERA, ERB), BMI, Metastasis statusAbstract
Background: Breast cancer (BC) is a heterogeneous disease witch produce from a number of genetic and epigenetic risks that lead to dysregulation of cell growth, circumvention of apoptosis, and development of the ability to invade the underlining tissue through the basement membrane. Aim: To assessment the association of BMI and age with positive receptors and metastasis status subtypes expression in Iraqi women of BC and determine the ERA and ERB and investigated the impact of those biomarkers alteration on the prognosis of patients with BC. Methods: This case-control study involved on 120 women with BC and same number as control group. Estimation of ERA and ERB were based on sandwich- ELISA. Results: The results examined that age and BMI of women with BC were significant associated with positive expression of ER and PR (p-value <0.05), but there were no association between those parameters and expression of Her-2 receptor subtype (pvalue >0.05). The results referred to a significant effects of age and BMI on expression of ER and PR in women with BC (OR=1.25 CI95%=0.49-3.51, OR=1.60 CI=0.61-4.16) (OR=1.4 CI95%=1.4-3.6, OR=1.83 CI95%=0.69-4.87), respectively. The results suggested the significant increase in incidence of IDC type of BC compare to ILC in women with (BMI ≥ 25) Conclusion: Assessment of ERA and ERB are useful in diagnosis and following up of women with BC in different ER, PR, ,Her-2, and in different histological grades.
Downloads
References
1- PDQ Screening and Prevention Editorial Board. PDQ Cancer Information Summaries. National Cancer
Institute (US); Bethesda (MD) (2018). Breast Cancer Screening (PDQ®): Health Professional Version.
2- Doren A, Vecchiola A, Aguirre B, Villaseca P. Gynecological-endocrinological aspects in women carriers of
BRCA1/2 gene mutations. Climacteric;2018,21(6):529-535.
3- Van Keymeulen A, Lee M, Ousset M, Brohee S, Rorive S, Giraddi R et al . Reactivation of multipotency by
oncogenic PIK3CA induces breast tumour heterogeneity. Nature. 2015,525:119–23.
4- Wooster R and Weber B. Breast and onvarian cancer. N Engl J Med; 2013,348(23):2339.
5- Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature.
2012,490:61–70.
6- Siegel R, Miller K and Jemal A. Cancer Statistics. CA Cancer J Clin. ;2017, 67:7–30.
7- DeSantis C, Fedewa S, Goding Sauer A et al. Breast cancer statistics. Convergence of incidence rates
between black and white women. CA Cancer J Clin. 2016;66:31–42.
8- Sarab K et al. Risk factors of breast cancer among Iraqi women. J Contemp Med Sci : 2019,5, (3):149–153
9- Runnak A, Hemin A, Dana N, , Hazha A, Michae D. Breast cancer in Iraq is associated with a unimodally
distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC
women's health .2017,17:27.
10- Brewer H, Jones M, Schoemaker M et al. Family history and risk of breast cancer: an analysis
accounting for family structure. Breast Cancer Res Treat.2017 ;165:193–200.
11- Thakur P, Seam RK, Gupta MK, Gupta M, Sharma M, Fotedar V. Breast cancer risk factor
evaluation in a Western Himalayan state: A case–control study and comparison with the Western World.
South Asian J Cancer.2017, 6(3):106–109.
12- Runnak A, Hemin A, Dana N, et al. Breast cancer in Iraq is associated with a unimodally
distributed predominance of luminal type B over luminal type A surrogates from young to old age. BMC
Women Health.2017; 17: 27.
13- Al-Anbari, S. Correlation of the clinicopathological presentations in Iraqi breast cancer patients
with the finding of bio field breast cancer diagnostic system (BDS), HER-2 and Ki-67 immunohistochemical
expressions. Ph.D thesis, College of medicine, University of Baghdad, 2009.
14- Al-Sanati, M. PCR Study of BRCA1 BRCA2 in Correlation to Immunohistochemical Expression
of p53, Estrogen and Progesterone Receptors in Breast Cancer. Ph.D thesis, College of medicine, University
of Baghdad, 2009.
15- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of
cancer: a systematic review and meta-analysis of prospective observational studies. Lancet.2008;371:569–
578.
16- Kang L, Weining Z, Zhiming D et al. Association between body mass index and breast cancer risk:
evidence based on a dose–response meta-analysis. Cancer Manag Res.2018; 10: 143–151.
17- Goldberg M et al. Early-Life Growth and Benign Breast Disease. Am J Epidemiol. 2019,
1;188(9):1646-1654.
18- Carol E et al. Breast Cancer Statistics, 2019. CA CANCER J CLIN.2019;69:438–451.
19- Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, Goncalves F. Bone Metastases: An
Overview. Oncology Reviews. 2017,11 (1): 321.
20- Riethdorf S, Müller V, Zhang L, et al. Detection and HER2 Expression of Circulating Tumor Cells:
Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial. Clin
Cancer Res. 2010;16(9):2634–45.
21- Bahriye A, Sabine K, Volkmar M. et al. Comparison of the HER2, estrogen and progesterone
receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast
cancer patients. BMC Cancer.2016; 16: 522.
22- Linares A et al. Increased expression of the HDAC9 gene is associated with antiestrogen resistance
of breast cancers. Mol Oncol.2019;13(7):1534-1547.
23- Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, Goh VH, Ridgway EC, Wierman
ME. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual
cycle and in postmenopausal women measured by liquid chromatography-tandem mass
spectrometry. Steroids.2011;76:177–82.
24- Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of
fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in
postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.J Clin
Oncol.2008; 26:1664.
25- Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R,
Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of
adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet.2011, 378(9793):771–84.
26- Yoko O and Hirotaka I. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci.2015; 106(4): 337–343.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
